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Abstract
Joint homeostasis failure can result in osteoarthritis (OA).
Currently, there are no treatments to alter disease progression
in OA, but targeting early changes in cellular behavior has
great potential. Recent data show that nuclear receptors con-
tribute to the pathogenesis of OA and could be viable thera-
peutic targets, but their molecular mechanisms in cartilage are
incompletely understood. This study examines global changes
in gene expression after treatment with agonists for four nu-
clear receptor implicated in OA (LXR, PPARδ, PPARγ, and
RXR). Murine articular chondrocytes were treated with ago-
nists for LXR, PPARδ, PPARγ, or RXR and underwent mi-
croarray, qPCR, and cellular lipid analyses to evaluate chang-
es in gene expression and lipid profile. Immunohistochemistry
was conducted to compare two differentially expressed targets
(Txnip, Gsta4) in control and cartilage-specific PPARδ knock-
out mice subjected to surgical destabilization of the medial
meniscus (DMM). Nuclear receptor agonists induced different
gene expression profiles with many responses affecting lipid
metabolism. LXR activation downregulated gene expression
of proteases involved in OA, whereas RXR agonism
decreased expression of ECM components and increased ex-
pression of Mmp13. Functional assays indicate increases in
cell triglyceride accumulation after PPARγ, LXR, and RXR
agonism but a decrease after PPARδ agonism. PPARδ and
RXR downregulate the antioxidant Gsta4, and PPARδ
upregulates Txnip. Wild-type, but not PPARδ-deficient mice,
display increased staining for Txnip after DMM. Collectively,
these data demonstrate that nuclear receptor activation in
chondrocytes primarily affects lipid metabolism. In the case
of PPARδ, this change might lead to increased oxidative
stress, possibly contributing to OA-associated changes.
Key message
& Nuclear receptors regulate metabolic genes in
chondrocytes.
& Nuclear receptors affect triglyceride levels.
& PPARδ mediates regulation of oxidative stress markers.
& Nuclear receptors are promising therapeutic targets for
osteoarthritis.
Keywords Cartilage . Chondrocyte . Lipid metabolism .
Osteoarthritis . Oxidative stress
Introduction
Dysregulation of joint homeostasis can result in osteoarthritis
(OA), a collective of heterogeneous pathologies culminating
in joint failure. OA presents with similar pathological end
points, but mechanisms of initiation and progression vary
among subtypes of this disease, which is one of the leading
causes of disability worldwide [1, 2]. Its varied presentation
influences whether it is symptomatic or not and even whether
it can be diagnosed radiographically. Multiple tissues, such as
the articular cartilage, subchondral bone, synovium, meniscus,
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and fat pads, are involved in this condition, and initiation of
this disease can stem from mechanical, metabolic, or age-
associated factors, although none of these are mutually
exclusive.
The main function of the cartilage is to act as a shock
absorber, mediating load bearing through the influx and
efflux of water attracted to the proteoglycan aggregates of
the extracellular matrix and through the tensile strength
conferred by collagen fibril organization [3]. Although
cartilage cells contribute a small percentage of the volume
of the entire joint, they are sensitive to external factors
and respond with changes in gene expression affecting
OA, thus underscoring their importance in joint
homeostasis.
Metabolic OA has been classified as a distinct subtype of
OA associated with disorders such as dyslipidemia, hyperten-
sion, and obesity [4]. Imbalances in systemic lipid and cho-
lesterol metabolism, nutrient exchange, accumulation of ad-
vanced glycation end products, and increases in adipokines
contribute to this condition. Changes in lipid metabolism, in
particular, may directly affect joint homeostasis through ec-
topic lipid deposition in chondrocytes [4–6]. In fact, both
chondrocyte-specific cholesterol accumulation and high-fat
diet have caused increased disease severity in murine models
[7–9]. Altogether, these data suggest direct regulation of car-
tilage homeostasis by lipid metabolism.
Nuclear receptors are a class of proteins that are activated
by small molecule ligands and can up- or downregulate the
expression of target genes through the recruitment of co-fac-
tors. They have been reported as attractive potential targets for
pharmacological therapy because of their ability to bind syn-
thetic or natural ligands that regulate transcriptional activity
[10]. As such, synthetic agonists for nuclear receptors have
been developed to target metabolic conditions such as dyslip-
idemia, atherosclerosis, and diabetes [11, 12]. Peroxisome
proliferated activated receptors (PPARs) are typically in-
volved in the control of lipid metabolism and activated by
the binding of endogenous fatty acids, whereas liver X recep-
tor (LXR) is principally involved in cholesterol metabolism.
Recently, we have shown that cartilage-specific ablation of the
gene encoding the nuclear receptor PPARδ has a protective
effect on cartilage after surgical induction of OA, demonstrat-
ing that PPARδ promotes post-traumatic OA. Conversely,
PPARγ and LXR are protective and necessary for normal joint
function and skeletal development [13–16]. Interestingly, all
three of these receptors act in heterodimers with the common
partner RXR, positioning RXR at the center of a complex
network of nuclear receptors. All of these proteins are
expressed in the cartilage [15, 17, 18]. However, the mode
of action of these proteins in the cartilage is largely unknown,
and since they are transcription factors, identification of their
target genes is essential to understand their specific roles and
to evaluate their value as therapeutic targets. Here, we
attempted to identify these target genes in a genome-wide
manner.
In this study, we have used microarray analysis paired with
functional validation to identify gene targets of LXR, PPARγ,
PPARδ, and RXR in articular chondrocytes, in order to eluci-
date their potential role in OA pathogenesis. There is strong
evidence implicating the involvement of nuclear receptors in
the progression or prevention of OA, and here, we provide
insight as to how they may be involved in altering the gene
expression profile and phenotype of mature, healthy chondro-
cyte cultures. We are also the first, to our knowledge, to quan-
tify changes in neutral lipid and free cholesterol mass in
chondrocytes in vitro. This information is essential in
uncovering the early changes that occur in chondrocytes be-
fore irreversible phenotypic changes within the joint and is
vital since we currently have no effective biomarkers or treat-
ment to alter the course of OA progression. Our data demon-
strate that changes in gene regulation after nuclear receptor
agonist treatment primarily affect lipid metabolism, suggest-
ing a close link between lipidmetabolismwithin chondrocytes
and the progression of OA.
Methods
Primary cell culture and isolation
Immature murine articular chondrocytes (IMACs) were iso-
lated from the femoral head, femoral condyle, and tibial con-
dyles of 5–6-day-old CD1 mice (Charles River Laboratories)
as per [19]. The tissue was then subjected to 1 h (3 mg/ml)
followed by 24 h (0.5 mg/ml) incubations in Collagenase D
diluted in Dulbecco’sModified EaglesMedium supplemented
with 2 mM l-glutamine, 50 U/ml penicillin, and 0.05 mg/ml
streptomycin at 37 °C under 5% CO2. The tissue fragments
were then agitated, and cells were isolated and cultured [19].
On the seventh day after isolation, cells were treated with
either PPARδ agonist (GW501516), PPARγ agonist
(Rosiglitazone), LXR agonist (GW3965), RXR agonist
(SR11237), or control (DMSO), all at concentrations of
1 μM for 72 h. Pyruvate dehydrogenase kinase (PDK) inhibi-
tion studies were done using these nuclear agonist treatments
and one of two inhibitors at 5 μM: dichloroacetate (DCA, pan-
PDK inhibitor) or diisopropylaminedichloroacetate (DADA,
PDK4 inhibitor), or vehicle control (water).
RNA extraction, purification, and qPCR
Total RNA was isolated from cells using TRIzol®
(Invitrogen). Cells were lysed in TRIzol® reagent, phases
were separated using chloroform (20%), and supernatant
was removed. RNAwas precipitated using 100% isopropanol
(0.5%) and washed using 70% ethanol followed by air-drying
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and resuspension in RNAse free water, as per manufacturer’s
instructions. RNA was quantified using a Nanodrop 2000
spectrophotometer. RNA integrity was confirmed with
Aligent 2100 BioAnalyzer Data Review Software
(Wilmington, DE) at the London Regional Genomics
Centre. Samples with RNA integrity number (RIN) values
greater than 8 were used for microarray analysis.
Real-time PCR (qPCR) was performed as per [16]. In brief,
qPCR was performed using a One-Step RT qPCRMaster Mix
kit and TaqMan Gene Expression Assays (Applied
Biosystems), with 40 cycles on an ABI Prism 7900HT se-
quence detector (PerkinElmer), or on a Bio-Rad CFX384
RT-PCR system with 10–15 μl reaction volumes of iQ
SYBR Green Supermix (Biorad) with diluted cDNA equiva-
lent to 200–500 ng of input RNA per reaction, as well as 25–





LPL(Mm00434764_m1), Mmp2 (Mm00439498_m1), Mmp3
(Mm00440295_m1), Mmp13 (Mm00439491_m1),
Pdk4(Mm01166879_m1), and Sox9 (Mm00448840_m1)
were purchased from Life Technologies. Gene expression
was normalized relative toActb or 18S (viability studies only).
Relative gene expression was calculated using the ΔΔCt
method [21] as described [22]. Statistical analysis was con-
ducted using GraphPad Prism 6.0. Values were transformed,
and a one-way analysis of variance (ANOVA) was performed
followed by Tukey’s multiple comparisons tests.
Microarray and data analysis
Total RNA (200 ng per sample) was subject to 2 rounds of
amplification followed by labeling and hybridization to
Affymetrix GeneChip®Mouse Gene 2.0 STArray containing
35,240 probes at the London Regional Genomics Centre
(London, Ontario, Canada) as described [23]. Three indepen-
dent cell and RNA isolations were used for each treatment.
Probe data was analyzed, and gene level, ANOVA p values,
and fold changes were determined using Partek Genomics
Suite v6.6. Genes with at least 1.5-fold change, with
p < 0.05 were considered significant and used for subsequent
analyses. The complete array data set will be publicly avail-
able through Gene Expression Omnibus (GEO). The Venn
diagrams were created using the online plotting tool Venny
2.0.1 [24]. KEGG pathway maps were generated using
Ingenuity Pathway Analysis. Gene ontology biological pro-
cesses and cellular component processes were classified
through GO consortium available at geneontology.org using
the PANTHER Overrepresentation Test (released 2016-07-15
) and GO Ontology Database (released 2016-10-27), Mus
musculus reference list, and Bonferroni correction for
multiple testing. Biological processes identified with more
than three genes involved were included in the table.
Cellular lipid mass
IMACs were isolated, cultured, and treated with nuclear re-
ceptor agonists as described above. At the 72 h time point,
cells were washed with 0.2% BSA in phosphate-buffered sa-
line (PBS), followed by three washes in PBS. Lipids were
extracted using 3:2 hexane/isopropanol solvent and pooled.
Hexane/isopropanol solvents were evaporated to dryness un-
der N2 and resuspended in 1.4 ml of chloroform–triton (0.5%
triton v/v). Solvent was re-evaporated, and lipids were re-
solubilized in 350 μl water. Two 50-μl aliquots were used
per sample to determine total cholesterol (TC), free cholesterol
(FC), and triglyceride (TG) mass, spectrophotometrically as
per [25]. Cholesteryl esters (CE) were calculated by
subtracting FC from TC. Proteins were extracted using 0.2
NaOH overnight incubation to digest chondrocytes and quan-
tified using a standard BCA protein assay (Pierce, Thermo
Fisher Scientific). All cell lipid measures reported are stan-
dardized to milligrams of cell protein. Values were normalized
relative to vehicle control DMSO, and statistical analyses
were performed using GraphPad Prism 6.0. Values were trans-
formed, and a one-way analysis of variance (ANOVA) was
performed followed by Tukey’s multiple comparisons tests.
Animals and surgery
All animal experiments were approved by the Animal Use
Subcommittee at The University of Western Ontario and were
conducted in accordance with the guidelines from the
Canadian Council on Animal Care. Mice were group housed
(6 mice per cage) in colony cages on a standard 12 h light/dark
cycle with free access to standard mouse chow, water, and
running wheels. Surgical destabilization of the medial menis-
cus (DMM) or SHAM surgerywas performed on 12-week-old
C57BL/6 male mice (N = 8–9 per group), as described in [13].
Mice were euthanized at 10 or 12 weeks post-surgery for
preparation of paraffin sections and subsequent histological
analysis. Another cohort of 20-week-old male cartilage-
specific Ppard knockout mice and wild-type littermate con-
trols underwent DMM surgery (N = 5 per group) and was
harvested for histological analyses 8 weeks later as in [13].
Ppard mutant mice were bred and genotypes as described in
[13]. Paraffin sections from these studies were employed to
evaluate the presence of Thioredoxin Interacting Protein
(Txnip) and glutathione S-transferase A4 (Gsta4).
Immunohistochemistry
Immunohistochemistry was performed on frontal sections of
paraffin-embedded knee joints as described [26]. Txnip rabbit
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polyclonal antibody was purchased from Proteintech (18243-
1-AP). Slides without primary antibody were used as controls,
antigen retrieval was performed in 0.1% Triton in H20, and
primary antibody was used at a concentration of 1:300. Gsta4
rabbit polyclonal antibody was purchased from Proteintech
(17271-1-AP), and immunohistochemical staining was per-
formed under the same conditions as above, except with a
primary antibody concentration of 1:100.
Results
Global changes in chondrocyte gene expression
in response to nuclear receptor agonists
We have previously reported that treatment of articular
chondrocytes with the PPARδ agonist GW501516 results in
increased catabolic gene expression and robust fatty acid ox-
idation. We have also determined that the LXR agonist
GW3965 delays chondrocyte hypertrophy [13, 16].
Identifying which genes are responsible for these phenotypes
and how they interact with each other is key to understanding
signaling pathways responsible for joint homeostasis and the
prevention of osteoarthritis. We first examined global changes
in chondrocyte gene expression in response to 1 μM treatment
with LXR agonist GW3965, RXR agonist SR11237, PPARδ
agonist GW501516, or PPARγ agonist Rosiglitazone. RNA
was isolated from IMACs cultured with agonists for 72 h, then
hybridized to Affymetrix microarrays representing the mouse
genome.
We compiled a list of genes changed by more than 1.5-fold
(refer to supplementary data for full list). LXR agonism sig-
nificantly altered 128 genes (97 upregulated, 31 downregulat-
ed), RXR agonism differentially regulated a total of 108 genes
(67 upregulated, 41 downregulated), PPARδ agonism induced
changes in 58 genes (48 upregulated, 10 downregulated),
while PPARγ agonism changed 32 genes (29 upregulated, 3
downregulated). The most robust and significantly upregulat-
ed and downregulated genes after nuclear receptor agonist
treatment are shown in Fig. 1.
Nuclear receptors affect common biological functions
in chondrocytes
Comparison of gene expression profiles induced by vari-
ous nuclear receptor agonists revealed several common
hits. We therefore decided to evaluate shared functional
roles by identifying similar biological processes through
Gene Ontology. Supplementary Table 1 indicates the bio-
logical processes regulated by agonist treatment for each
nuclear receptor, and common processes are highlighted
with the same color. Both LXR and RXR agonism altered
cholesterol biosynthetic processes, while LXR and
PPARγ regulated triglyceride metabolism, and RXR and
PPARγ increased metabolic processes in chondrocytes.
We also investigated GO cellular component processes
affected by each agonist (Supplementary Table 2). We
noted that the extracellular matrix, mitochondrion, mito-
chondrial membrane, and endoplasmic reticulum were key
areas in these processes, and that lipid particles and ex-
tracellular space were common between at least two treat-
ment groups. The identified cellular components were
consistent with our biological processes, heavily implicat-
ing the metabolic functions of these nuclear receptor ag-
onists. In order to compare relationships between nuclear
receptor agonist treatments, we created a Venn diagram to
illustrate the number of genes induced by multiple recep-
tors (Fig. 2a). The two genes upregulated by all four nu-
clear receptor agonists were Pdk4 and Angptl4. Pdk4
functions as an inhibitor of the pyruvate dehydrogenase
complex. Thus, it plays a key regulatory role in shifting
energy utilization from glycolytic to fatty acid metabolism
in the cell [27]. Angptl4 is a well-known direct target of
PPARs that is upregulated by hypoxia and has been char-
acterized as an adipocytokine [28]. It has also been iden-
tified as a potential pro-angiogenic mediator of arthritis, is
involved in ECM remodeling, and is upregulated in the
cartilage of RA and OA patients [29–31]. Larger numbers
of genes were regulated by two or three different agonists
(Fig. 2a), and differences in gene regulation between the
commonly induced genes are hierarchically clustered and
visually represented in a heatmap (Fig. 2b).
KEGG pathway analysis was subsequently conducted to
identify whether the genes common among agonist treatment
would be associated with shared processes. We discovered
that the four agonists shared 13 common pathways (Fig. 3).
Of these, the most significantly enriched pathways included
the PPAR signaling pathway and the adipocytokine signaling
pathway (Supplementary Figs. 1 and 2). According to our
analyses, all four nuclear receptors are involved in adipocyte
differentiation and fatty acid transport. While LXR, PPARγ,
and RXR regulate lipogenesis and LXR, PPARδ, and RXR
mediate fatty acid oxidation and beta oxidation, only PPARδ
agonism induces the ketogenic pathway.
Since PPARδ has opposite effects on OA progression than
PPARγ and LXR,wewere particularly interested in genes show-
ing opposite responses to the respective agonists. However, the
only gene that was differentially regulated (at our selected thresh-
old) between any of the treatments was Txnip, which encodes the
Thioredoxin interacting protein. Txnip inhibits Thioredoxin and
contributes to ER stress, inflammasome activation, and the accu-
mulation of reactive oxygen species (ROS) [32]. This gene was
upregulated by PPARδ agonist GW501516 and downregulated
by LXR agonist GW3965 treatment (Fig. 2b). Based on the
common pathways and genes identified, we next validated
changes in the expression of selected genes by qPCR.
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LXR, RXR, and PPAR agonism promote changes in genes
involved in ECM homeostasis and chondrocyte
metabolism
Genes induced in the microarray were primarily involved in
metabolic processes or in extracellular matrix component pro-
duction and turnover. We chose to validate a subset of these
genes that were shared between nuclear receptor agonist treat-
ments. Aggrecan and Fibrillin 2 are extracellular matrix pro-
teins encoded by the Acan and Fbn2 genes. In concert with
our microarray results, gene expression of Acan was signifi-
cantly lower than vehicle control (DMSO) with RXR agonist
treatment. Similarly, both LXR and RXR agonism significant-
ly lowered gene expression of Fbn2 (Fig. 4). Gene expression
of Collagen 2 (Col2a1) remained unchanged in response to
any of the treatments. Next, we validated expression of prote-
ase genes that were changed by some of the nuclear receptor
agonists and accordingly found that gene expression of
Adamts4, Mmp2, and Mmp13 were significantly reduced by
LXR agonism. Interestingly, RXR agonism decreased gene
expression of Adamts4 while increasing that of Mmp13 (the
primary collagenase of OA), implying a selective pathway for
ECM remodeling and degradation.
LXR, RXR, and PPARs are involved in the regulation of
metabolism in a number of tissues. In a previous study, we
showed that chondrocytes express functional PPARδ and are
capable of responding to GW501516 stimulation with in-
creased fatty acid oxidation [13]. All four nuclear receptor
agonists induced strong effects on genes encoding metabolic
enzymes. Angptl4 and Pdk4, the two common genes induced
by all four nuclear receptors in the microarray, demonstrated a
similar robust upregulation in qPCR validation (Fig. 5).
Abca1, Cidea, Cpt1a, Lpl, and Insig1 were significantly in-
creased by PPARδ, LXR, and RXR agonist treatment, and
LXR also significantly increased the expression of Srebf1.
Gene expression of cytoskeletal fatty acid transporter Fabp3
was significantly increased by PPARδ activation, while
Gsta4, a gene encoding an enzyme for cellular defense against
reactive electrophiles [33], was significantly reduced by both
PPARδ and RXR agonism.
In a previous study, our group has examined the toxicity of
the administration of PPARδ agonist GW501516; we have
shown that it does not alter cell number [13], while LXR
stimulation increases cell number [16]. Here, we examined
whether administration of any of the four nuclear receptor
agonists affects cell physiology through changes in gene ex-
pression of markers for proliferation (Ccnd1c, Pcna), cell cy-
cle exit (p57/Cdkn1c), apoptosis (Bax), or hypertrophic differ-
entiation (ColX, Runx2) (Supplementary Fig. 3). We do not
see any changes in these parameters, with the exception of
RXR agonism decreasing the expression of Runx2.
Increased expression of oxidative stress markers
in osteoarthritic cartilage
Txnip plays an important regulatory role in mediating oxida-
tive stress and inflammation in a number of tissues [32]. Txnip
was the only gene differentially regulated between nuclear
receptor agonists. LXR agonist treatment downregulated gene
expression, while PPARδ highly induced Txnip. These
Fig. 1 Microarray analyses of
nuclear receptor agonist effects on
chondrocyte gene expression.
Microarray analysis of RNA
isolated from immature murine
articular chondrocytes treated for
72 h with 1 μM LXR agonist
GW3965 (a), RXR agonist
SR11237 (b), PPARδ agonist
GW501516 (c), or PPARγ
agonist Rosiglitazone (d). The
most highly upregulated and
downregulated genes are shown
with fold change relative to
vehicle control DMSO (1 μM)
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patterns observed in microarray analyses were evaluated by
qPCR, where PPARδ agonism significantly increased gene
expression of Txnip, while LXR agonist-treated cells demon-
strated trends toward decreased gene expression, and RXR
and PPARγ agonism showed no change (Fig. 6a). To examine
whether Txnip expression is linked to OA, immunohisto-
chemistry for Txnip was performed on frontal sections of mice
after DMM surgery (Fig. 6b, c). Wild-type mice 10 weeks
post-surgery had increased staining in remaining cartilage
compared to mice that underwent sham surgery. To validate
the effects of PPARδ on Txnip expression, we compared pro-
tein expression in cartilage-specific Ppard KOmice and wild-
type littermates 8 weeks after DMM surgery. Wild-type mice
demonstrated increased staining for Txnip after DMM sur-
gery, particularly in areas of osteophyte growth at joint mar-
gins, whereas both sham-operated control mice and KO mice
after either surgery showed little to no staining. The apparent
increase of Txnip expression in the process of OA implies an
imbalance in regulatory processes governing oxidative stress
and inflammation, potentially linking changes in metabolism
to osteoarthritic changes.
In our qPCR validation of target genes, we saw decreased
expression of Gsta4 (Fig. 7a) after PPARδ and RXR agonist
treatment. Gsta4 protects the cell from reactive aldehydes that
are produced as a result of lipid peroxidation or oxidative
stress. We assessed the localization of Gsta4 in the DMM
model and found that sham-operated animals displayed con-
sistent immunohistochemical staining in superficial cartilage
and meniscus, both in wild-type and cartilage-specific Ppard
KOmice (Fig. 7b, c). DMM-operated animals showed little to
no staining in cartilage of both genotypes, even if superficial
cartilage remained intact.
Fig. 2 Comparison of nuclear
receptor agonist effects on
chondrocyte gene expression. a
Comparison of all genes regulated
by the four different nuclear
receptor agonists on chondrocytes
demonstrates that two genes are
commonly regulated by all four
nuclear receptors. Nine genes are
commonly regulated by LXR,
PPARδ, and RXR, while four
genes are commonly regulated by
LXR, PPARδ, and PPAR γ.
Three genes are regulated by
LXR, PPARγ, and RXR, and two
genes are commonly regulated by
PPARδ, PPARγ, and RXR. b
Differences in regulation of genes
commonly changed by all four
nuclear receptor agonism are
analyzed through hierarchical
clustering and visually displayed
in a heatmap
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Fig. 4 Effects of nuclear receptor agonist treatments on extracellular
matrix gene expression in chondrocytes. IMACs were incubated for
72 h with 1 μM DMSO (vehicle control), PPARδ agonist GW501516,
PPARγ agonist Rosiglitazone, LXR agonist GW3965, or RXR agonist
SR11237. a Relative gene expression of Acan gene is significantly
reduced by treatment with the RXR agonist. b, c Relative gene
expression of Adamts4 and Fbn2 are significantly reduced by LXR and
RXR agonist treatment. d, e Relative gene expression of matrix
metalloproteinases Mmp2 and Mmp13 is decreased by LXR agonist
treatment, while gene expression of Mmp13 is significantly elevated by
RXR agonist treatment. f Col2a1 gene expression remains unchanged by
all treatments. Values represented are the mean ± SEM of ≥3 independent
cell isolations. *p < 0.05
Fig. 3 Comparison of nuclear
receptor agonist effects on
affected KEGG pathways.
Comparison of all KEGG
pathways enriched by the four
different nuclear receptor agonist
treatments in chondrocytes
demonstrates that 13 pathways
are commonly enriched by all
four nuclear receptors. Seventeen
pathways are commonly enriched
by LXR, PPARδ, and RXR,while
two pathways are commonly
enriched by LXR, PPARδ, and
PPARγ. Five pathways are
commonly enriched by LXR,
PPARγ, and RXR, and no
pathways are commonly enriched
by PPARδ, PPARγ, and RXR
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Changes in gene expression correspond with functional
changes in chondrocyte lipid profile
In light of the number of genes involved in lipid metabo-
lism that were identified in our gene expression analyses,
we assessed neutral lipid and cholesterol accumulation in
chondrocytes. Using the same nuclear receptor agonist
treatment protocols, we harvested IMACs for cellular lip-
id mass assays. These assays allowed us to directly quan-
tify triglycerides and cholesterol in vitro. There were sig-
nificant changes in cell triglycerides, but not total choles-
terol, free cholesterol, or cholesteryl esters (Fig. 8). These
data suggest that changes in lipid metabolism upon ago-
nist treatment are likely related to lipogenesis and fatty
acid oxidation, rather than cholesterol transport or accu-
mulation. In particular, triglycerides were significantly de-
creased with PPARδ agonist treatment and were signifi-
cantly elevated with LXR, PPARγ, and RXR agonism.
These changes are consistent with the known effects of
activation of these nuclear receptors on triglyceride me-
tabolism in other cell types and suggest that PPARδ may
have an oppos ing ro le in l ip id metabo l i sm in
chondrocytes relative to the other nuclear receptors exam-
ined [34].
We investigated whether altering metabolic pathways
would affect lipid metabolism in chondrocytes treated with
the nuclear receptor agonists. Given the effects of all agonists
on Pdk4, we performed inhibition of pyruvate dehydrogenase
Fig. 5 Effects of nuclear receptor agonist treatment on metabolic gene
expression in chondrocytes. IMACs were incubated for 72 h with 1 μM
DMSO (vehicle control), PPARδ agonist GW501516, PPARγ agonist
Rosiglitazone, LXR agonist GW3965, or RXR agonist SR11237. a, c,
d, g, iRelative gene expression of Abca1, Cidea, Cpt1a, Lpl, and Insig1 is
significantly increased by PPARδ, LXR, and RXR treatments. b, f
Relative gene expression of Angptl4 and Pdk4 is elevated by all four
treatments. e Relative gene expression of Fabp3 is significantly
upregulated by PPARδ agonism only. g RXR and PPARδ treatment
significantly decreased relative gene expression of Gsta4. h Srebf1
expression is significantly upregulated by LXR agonism only. Values
represented are the mean ± SEM of ≥3 independent cell isolations.
*p < 0.05
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kinase with a pan-PDK inhibitor (DCA) or PDK4 specific
inhibitor (DADA) (Supplementary Fig. 4). PDK enzymes
act to inhibit pyruvate dehydrogenase which catalyzes the first
step of the pyruvate dehydrogenase complex (PDC). The PDC
oxidizes pyruvate to generate acetyl-coA to be used in the
TCA cycle, thereby promoting the preferential oxidation of
glucose. Either treatment did not affect the responses of chon-
drocyte triglyceride levels to the four agonists.
Discussion
This study is among the first to examine changes in global
gene expression in chondrocytes after nuclear receptor
agonist treatment, particularly paired with concurrent
functional analysis. It provides compelling evidence that
nuclear receptors drive early changes in cell metabolism
that can influence deleterious changes in cellular pheno-
type leading to the progression of OA. Nuclear receptors
have been increasingly linked to the progression of OA.
We have previously established the degenerative changes
promoted by PPARδ agonism in cartilage, as well as the
beneficial and necessary role of PPARγ in cartilage [13,
14]. We and others have characterized the protective role
of LXR in osteoarthritis [16, 35, 36]. However, in order to
establish how or whether these ligand-activated receptors
are feasible therapeutic targets, we must examine the mo-
lecular changes linked to activation or inhibition of each
factor.
We used IMACs treated with LXR, RXR, PPARγ, or
PPARδ agonists for 72 h. Immature murine articular
chondrocytes provide a large number of cells for analyses
Fig. 6 Effects of nuclear receptor
agonist treatment on Txnip
expression. a IMACs were
incubated for 72 h with 1 μM
DMSO (vehicle control), PPARδ
agonist GW501516, PPARγ
agonist Rosiglitazone, LXR
agonist GW3965, or RXR agonist
SR11237. PPARδ treatment
significantly increased gene
expression of Txnip. Values
represented are the mean ± SEM
of 4 independent cell isolations.
*p < 0.05. b
Immunohistochemistry for Txnip
demonstrates increased cellular
staining in the cartilage of WT
DMM mice 10 weeks post-
surgery relative to sham mice. c
Immunohistochemical staining
for Txnip in cartilage-specific
Ppard KO mice vs WT littermate
controls 8 weeks post DMM sur-
gery. Ppard KO mice display less
staining than WT mice
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on fully differentiated primary chondrocytes while mini-
mizing dedifferentiation [19]. Microarray analyses of
IMACs revealed changes in metabolic and ECM genes
in response to these agonists; these changes were largely
confirmed by qPCR. Agonism of RXR decreased gene
expression of the major ECM component aggrecan and
increased the expression of ECM protease Mmp13, while
LXR agonism decreased the gene expression of proteases
Adamts4, Mmp2, and Mmp13. Of particular interest were
the increases in expression of genes involved in lipid me-
tabolism since they showed greater induction than those
regulating ECM turnover. Among these genes, two were
induced by all four agonists, Pdk4 and Angptl4, suggest-
ing that they might play central roles in cartilage metab-
olism. Interestingly, in an earlier study, we had also dem-
onstrated increased expression of Pdk4 in response to
dexamethasone, a ligand for the glucocorticoid receptor
which is another member of the nuclear receptor family
[37].
Functional evaluation of lipid metabolism using cellular
lipid mass assays demonstrated a significant decrease in tri-
glycerides after PPARδ agonist treatment. Conversely, triglyc-
erides were significantly increased with PPARγ, LXR, and
RXR agonists. This is not surprising as PPARγ can often act
antagonistically to PPARδ with regard to lipogenesis [38],
while LXRmediates fatty acid biosynthesis through activation
of genes such as Srebf1, Fasn, and Scd1 which corroborates
our data (see GEO dataset) [39, 40]. Quantification of cell
lipids in vitro enables us to assess differences in some aspects
of lipid metabolism between treatments. In fact, it is plausible
that the dysregulation in lipid metabolism that we observed
could initiate metabolic changes in the cell that eventually lead
to apoptosis, inflammation, or changes in cell behavior, such
as synthesis of catabolic factors. Increased lipid deposition in
Fig. 7 Effects of nuclear receptor
agonist treatment on Gsta4
expression. a IMACs were
incubated for 72 h with 1 μM
DMSO (vehicle control), PPARδ
agonist GW501516, PPARγ
agonist Rosiglitazone, LXR
agonist GW3965, or RXR agonist
SR11237. PPARδ agonist
treatment and RXR agonist
treatment both significantly
decreased gene expression of
Gsta4. Values represented are the
mean ± SEM of 4 independent
cell isolations. *p < 0.05. b
Immunohistochemistry for Gsta4
demonstrates decreased cellular
staining in the cartilage of WT
DMM mice 12 weeks post-
surgery relative to sham mice. c
Immunohistochemical staining
for Gsta4 in cartilage-specific
Ppard KO mice vs WT littermate
controls 8 weeks post-DMM or
sham surgery. Both WT and
Ppard KO mice display little to
no staining of Gsta4 in the articu-
lar cartilage after DMM surgery,
compared to sham controls.
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osteoarthritic cartilage has been shown, while increased reac-
tive oxygen species (ROS) can cause lipid peroxidation,
which in turn could cause oxidative stress, resulting in degen-
erative changes to the matrix through oxidation of collagen II
[6]. We also sought to reduce the dysregulation of cell lipids
through the pharmacological inhibition of PDK, which would
increase ATP synthesis through glucose oxidation [41].
However, we found that further attempting to shift the pre-
ferred metabolic pathway away from fatty acid oxidation by
promoting an alternate pathway did not change cellular tri-
glyceride levels and agonist responses.
In addition to dysregulation of cell lipids, we also
see significantly decreased Gsta4 expression after
PPARδ or RXR agonist treatment. The encoded enzyme
Glutathione S-transferase A 4 protects against HNE (4
Hydroxynonal)-induced damage in chondrocytes. HNE
is an extremely reactive aldehyde produced from ROS
and lipid peroxidation and is increased in synovial fluid
from OA patients [40] as well as articular cartilage [42].
HNE can also post-transcriptionally modify Collagen 2
and MMP13 to induce degradative changes in cartilage
as well as changes in cell–matrix interactions [43, 44].
Molecularly, it has been observed that HNE can stimu-
late COX-2 via the ATF/cAMP response element and
inhibits iNOS and NF-kB inactivation in human articu-
lar chondrocytes [45]. GSTs are major determinants of
intracellular HNE concentration, and dysregulation in
disease states can result in toxic effects [46]. The
GSTA4 isoform has well-established selectivity and ef-
ficiency for conjugation of lipid peroxidation products,
especially HNE [46, 47]. Accordingly, decreased levels
of GSTA4 are present in human OA cartilage, making
the cartilage more susceptible to damage [33]. In addi-
tion, IL-1β treatment of human articular chondrocytes
decreases expression of GSTA4, while inhibition of the
p38 MAPK pathway (an important signaling pathway in
the pathogenesis of OA) increases levels of GSTA4 [48].
This suggests that the catabolic effects of PPARδ (and
possibly RXR) in cartilage could be partially due to the
decreased expression of Gsta4, resulting in decreased
anti-oxidant defense and thus increased oxidative stress.
In our surgical model of DMM induction, we see that
even the minimal damage experienced by PPARδ KO
after surgery is enough to decrease the expression of
this protein in vivo, indicating that Gsta4 is an early
response gene to damage and that there may be multiple
pathways that influence its regulation.
Another gene of interest , Txnip (thioredoxin
interacting protein), was highly induced by PPARδ
agonism, but appeared repressed by LXR agonism, in
agreement with the opposing effects of these nuclear
receptors on OA progression. Thioredoxin is another
Fig. 8 Quantification of cellular lipid mass in nuclear receptor agonist-
treated chondrocytes. IMACs were incubated for 72 h with 1 μMDMSO
(vehicle control), PPARδ agonist GW501516, PPARγ agonist
Rosiglitazone, LXR agonist GW3965, or RXR agonist SR11237.
Lipidswere extracted, isolated, andmass wasmeasured spectrophotomet-
rically. Proteins were isolated and quantified using BCA. Measurements
are reported relative to mg of cell protein. Absolute mean values for
triglycerides, total cholesterol, free cholesterol, and cholesterol esters
were 7.4, 27.1, 26.4, and 0.75 μg/mg protein, respectively, for DMSO-
treated cells. a Cell triglycerides (μg) are significantly elevated by
PPARγ, LXR, and RXR treatment and are significantly decreased by
PPARδ agonism. b, c, d Total cholesterol, free cholesterol, and choles-
terol ester remain unchanged after nuclear receptor agonist treatment.
Values represented are the mean ± SEM of ≥5 independent cell isolations.
*p < 0.05
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important antioxidant, but binding of Txnip to
thioredoxin inhibits its ability to scavenge for ROS
[49]. In humans, decreased TXNIP is seen at late stages
of OA, while increased TXNIP is seen in H2O2-induced
cartilage damage in human chondrocytes [50, 51]. In
our study, we demonstrate increased gene expression
of Txnip after PPARδ agonism in chondrocytes, and
control mice show increased staining for Txnip after
DMM surgery. The apparent differences in Txnip regu-
lation in human and mouse OA are likely due to the
different disease stages; human data were obtained from
end-stage samples, while the DMM model is subtle and
our analyses have largely focused on mild to moderate
disease. We also show that cartilage-specific Ppard
knockout mice that are protected against cartilage de-
generation in the DMM model have decreased Txnip
staining after DMM surgery, in line with our microarray
data. Txnip has been linked to oxidative stress and in-
flammation, and it can directly activate NF-kB and
downs t r eam in f l ammato ry cy tok ines [52 ] . In
chondrocytes, recent work has shown that Redd1 can
form a complex with Txnip to regulate autophagy
[53]. Taken altogether, these data help to form a cohe-
sive picture of how changes in cell metabolism could
influence the development of early osteoarthritis.
Nuclear receptors appear to play a key role in these
processes by regulating the expression of central players
such as Txnip and Gsta4.
Current treatment strategies for OA are largely ineffective
or inconclusive. It is possible that we are missing a critical
temporal period during which chondrocyte homeostasis is
disrupted, later leading to matrix degeneration. Recent evi-
dence demonstrates that nuclear receptors are key regulators
of OA pathogenesis, and the data presented here suggests that
their primary targets are metabolic regulation. Metabolic de-
regulation, in turn, can trigger events leading to oxidative
stress and inflammation, protease activation, and ultimately
cartilage degeneration. Targeting these critical processes could
be a promising avenue for treatments that alter disease
progression.
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